THE JOHNS HOPKINS UNIVERSITY and Bristol-Myers Squibb Co. announced a five-year collaboration aimed to answer why some patients respond to checkpoint blockers and some do not, and to develop more effective combination immunotherapies. Projects included in the collaboration will span laboratory research on patients’ tumor samples and several early-stage clinical trials led by Johns Hopkins...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
